Liver Fibrosis

An aerobic exercise program may help improve histologic endpoints in patients with metabolic dysfunction associated fatty liver disease, according to study results.

Among U.S. adults with type 2 diabetes attending primary care and endocrinology clinics, less than 40% of those found to have liver fibrosis had elevated aspartate aminotransferase and alanine aminotransferase, according to study data.

Biopsy-confirmed fibrosis was associated with risk for mortality and liver-related morbidity in patients with NAFLD, regardless of confounding factors and in patients with NASH, according to study results.

Both the fatty liver inhibition of progression algorithm and the steatosis activity and fibrosis scoring system identified distinct clinical and biological profiles of disease severity among patients with suspected nonalcoholic fatty liver disease.

Akero Therapeutics announced that it has completed enrollment for a phase 2a study of AKR-001, the company’s FGF21 analog candidate for the treatment of nonalcoholic steatohepatitis, according to a press release.

Poxel announced positive safety, tolerability and pharmacokinetic results from a phase 1b multiple ascending dose trial of PXL065, a deuterium-stabilized R-stereoisomer of Actos under investigation for nonalcoholic steatohepatitis, according to a press release.

Patients with autoimmune hepatitis who had a rapid response after treatment were the most likely to achieve normalization of transaminase levels in the following year and had a lower risk for liver-related death or transplantation, according to results of a retrospective study.

Results from the phase 2 ATLAS study showed that neither monotherapy nor combined therapy with cilofexor reached the endpoint of significant improvement in fibrosis stage without worsening of nonalcoholic steatohepatitis, according to a press release from Gilead Sciences.

Patients with current or prior hepatitis C infection were willing to engage in alcohol intervention including counseling and referral to treatment when encouraged by liver medical providers, according to data published in Hepatology.

Alcohol use was a significant risk factor for clinically defined nonalcoholic fatty liver disease due to association with alcohol use and liver fat, according to recently published data.